vimarsana.com

Page 18 - வாழ்நாள் தொடர்புடையது மாகுலர் சீரழிவு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

LumiThera Completes Patient Enrollment in the U S Multi-Center, LIGHTSITE III Clinical Study to Treat Dry Age-Related Macular Degeneration

Here are the Lesser Known Benefits of Consuming Omega-3

New method can help evaluate potential sight-preserving properties

New method can help evaluate potential sight-preserving properties Scientists like the John A. Moran Eye Center s Paul S. Bernstein, MD, PhD, know a special class of lipids, or fatty acids, found in the retina of the eye and in just a few other parts of the body play an important role in maintaining vision. But it s been difficult to study whether giving these lipids, called very-long-chain polyunsaturated fatty acids (VLC-PUFAs), to patients as a supplement could prevent blinding eye diseases like age-related macular degeneration, diabetic retinopathy, and some inherited retinal diseases. Made in the body by the ELOVL4 enzyme but rarely consumed as part of a normal diet, VLC-PUFAs weren t commercially available in enough quantities for animal or human research.

MENA Biologics & Biosimilars Market to Surpass US$ 623 7 by 2027, Says Coherent Market Insights (CMI)

US$ 442.5 million in 2020 and is expected to exhibit a CAGR of 3.9% during the forecast period (2020-2027). Key Trends and Analysis: The MENA biologics & biosimilars market is expected to witness significant growth, owing to increasing prevalence of Age-related Macular Degeneration (AMD). For instance, according to the study in Saudi Medical Journal 2015, in Saudi Arabia, AMD represents 3.3% of the major causes of blindness in individuals older than 50 years. The increasing approval and new drug launches are expected to propel the market growth. For instance, in 2017, Swedish Orphan Biovitrum AB (Sobi) received Saudi Food & Drug Authority (SFDA) approval for Elocta (efmoroctocog alfa), a recombinant human factor VIII Fc-fusion protein with an extended half-life, for the treatment of hemophilia A.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.